- Clinical Technology
- Adult Immunization
- Hepatology
- Pediatric Immunization
- Screening
- Psychiatry
- Allergy
- Women's Health
- Cardiology
- Pediatrics
- Dermatology
- Endocrinology
- Pain Management
- Gastroenterology
- Geriatrics
- Infectious Disease
- Obesity Medicine
- Rheumatology
- Oncology
- Nephrology
- Neurology
- Pulmonology
Chronic Hand Eczema: Clinical Insights and Future Directions from RAD 2025
RAD 2025: Explore expert insights on chronic hand eczema, its differences from atopic dermatitis, and emerging treatments in this informative video series.
In this 4-part video series from the Revolutionizing Atopic Dermatitis (RAD) 2025 meeting, Jiade Yu, MD, director of the Contact Dermatitis Clinic at Massachusetts General Hospital, shared expert insights on chronic hand eczema (CHE)—a condition often mischaracterized and undertreated. Dr Yu discussed how CHE differs from atopic dermatitis (AD), the real-world burden it places on patients, and advances in treatment that may soon improve care. Each segment captured one key question and response from the interview, offering concise and clinically relevant takeaways for physicians managing chronic inflammatory skin conditions.
For more RAD 2025 meeting coverage, please click here.
Lebrikizumab Demonstrates Efficacy, Safety in Patients With Skin of Color With AD
June 11th 2025RAD 2025. Lebrikizumab improved skin clearance, itch, and pigmentation in patients with skin of color and atopic dermatitis, with strong safety data through 24 weeks, according to late-breaking data.
